Work

Cross-Organ Differences Between IL-4Rα Blockade and IL-13-Selective Therapy in Immune-Priming and Barrier-Effector Compartments: Implications for Skin, Airway, and Gastrointestinal Diseases

Year: 2026
Type: article
Abstract: Antibody therapies targeting the IL-4/IL-13 axis are used in type 2 inflammatory diseases affecting skin, airways, and gastrointestinal tissues. Clinical responses and biomarker behavior differ across organs, complicating trial interpretation and endpoint selection. We propose an IL-4Rα-centered framework that relates these differences to receptor-responsive cells, local cytokine supply, and the compartments sampled by each endpoint. Type I receptors (IL-4Rα/γc) support IL-4-dependent immune priming, including type 2 helper T-cell (Th2) differentiation and immunoglobulin E (IgE) class switching. Type II receptors (IL-4Rα/IL-13Rα1) respond to both IL-4 and IL-13 and are prominent in epithelial and mesenchymal effector programs. Selected immune populations also respond through Type II receptors. We connect receptor biology to organ-specific experimental mechanisms and clinical outcomes, distinguish within-cell receptor expression from tissue cellular composition, and consider IL-13Rα2 as a separate ligand-buffering regulator. These assignments are predominant tendencies rather than exclusive cellular localizations or validated treatment-selection rules. This approach links molecular, tissue, and clinical endpoints while avoiding claims of drug superiority based on cross-trial comparisons.
Source: Receptors
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,207
OpenAlex ID: W7234003926
FWCI:
Cites: 110
Cited by:
Related to: 10